Statements (61)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:chemical_compound
|
gptkbp:bfsLayer |
5
|
gptkbp:bfsParent |
gptkb:Plasmodium
|
gptkbp:activities |
inhibits heme polymerization
|
gptkbp:affects |
immune response
inflammatory response viral replication |
gptkbp:appointed_by |
oral tablet
|
gptkbp:approves |
gptkb:FDA
|
gptkbp:brand |
Aralen
|
gptkbp:can_be_used_with |
gptkb:azithromycin
zinc |
gptkbp:clinical_trial |
Phase 2
Phase 3 |
gptkbp:composed_of |
gptkb:chemical_compound
synthesized from quinine |
gptkbp:contraindication |
retinal disease
hypersensitivity to chloroquine |
gptkbp:developed_by |
German scientists
|
gptkbp:discovered_by |
1934
|
gptkbp:displacement |
from plasma proteins
|
gptkbp:dissolved |
soluble in water
soluble in ethanol insoluble in ether |
gptkbp:dosage_form |
250 mg daily for autoimmune diseases
500 mg weekly for malaria |
gptkbp:excretion |
primarily through urine
|
gptkbp:global_presence |
widely used in developing countries
used in malaria-endemic regions |
gptkbp:historical_significance |
used during World War II
first effective treatment for malaria |
https://www.w3.org/2000/01/rdf-schema#label |
chloroquine
|
gptkbp:ingredients |
C18 H26 Cl N3
|
gptkbp:interacts_with |
antacids
certain antibiotics anticonvulsants |
gptkbp:invention |
patent expired
|
gptkbp:is_analyzed_in |
gptkb:drug
|
gptkbp:is_available_on |
generic drug
|
gptkbp:is_used_for |
treatment of autoimmune diseases
treatment of malaria |
gptkbp:lifespan |
3 to 5 days
|
gptkbp:marketed_as |
various pharmaceutical companies
|
gptkbp:metabolism |
liver
|
gptkbp:related_to |
hydroxychloroquine
|
gptkbp:research_focus |
pharmacokinetics
anti-inflammatory properties drug resistance antiviral properties |
gptkbp:safety_features |
Category C in pregnancy
|
gptkbp:side_effect |
dizziness
headache nausea skin rash hypoglycemia hepatotoxicity visual disturbances cardiotoxicity |
gptkbp:storage |
store at room temperature
protect from light |
gptkbp:weight |
319.85 g/mol
|